Previous Article | Next Article ![]()
Journal of Virology, November 2001, p. 10808-10814, Vol. 75, No. 22
Department of Cancer Immunology and AIDS,
Dana-Farber Cancer Institute,1
Departments of Pathology,2
Medicine,3 and
Pediatrics,6 Harvard Medical School,
Department of Immunology and Infectious Diseases, Harvard
School of Public Health,5 Division of
Rheumatology, Immunology and Allergy, Brigham and Women's
Hospital,4 and Partner's Asthma
Center,7 Boston, Massachusetts
Received 21 May 2001/Accepted 1 August 2001
Mast cells are critical components of innate and adaptive immunity
that differentiate in tissues in situ from circulating committed
progenitor cells. We now demonstrate that human cord blood-derived mast
cell progenitors are susceptible to infection with macrophagetropic
(M-tropic) and dualtropic human immunodeficiency virus type 1 (HIV-1)
isolates but not with T-cell-tropic (T-tropic) strains. Mast cell
progenitors (c-kit+ CD13+ cells
with chloroacetate esterase activity) were purified from 4-week-old
cultures of cord blood mononuclear cells maintained in stem cell
factor, interleukin-6 (IL-6), and IL-10 using a CD14 depletion column.
These progenitors expressed CCR3, CCR5, and CXCR4, as well as low
levels of CD4. When infected in vitro with viruses pseudotyped with
different HIV and simian immunodeficiency virus envelope glycoproteins,
only M-tropic and dualtropic, but not T-tropic, viruses were able to
enter mast cell progenitors. Both the CCR5-specific monoclonal antibody
2D7 and TAK-779, a nonpeptide inhibitor of CCR5-mediated viral entry,
blocked HIV-1 strain ADA infection by >80%. Cultures infected with
replication-competent virus produced progressively increasing amounts
of virus for 21 days as indicated by p24 antigen detection. Mast cell
progenitors that were exposed to an M-tropic, green fluorescent
protein-expressing HIV-1 strain exhibited fluorescence indicative of
viral entry and replication on a single-cell level and retained virus
production during differentiation. The trafficking of mast cell
progenitors to multiple tissues, combined with the long life span of
mature mast cells, suggests that they could provide a widespread and persistent HIV reservoir in AIDS.
Mast cells (MC) are immune effector cells residing
in perivascular connective tissues and mucosal surfaces
(22). They arise in situ by a stem cell factor
(SCF)-dependent mechanism from a population of bone marrow-derived
circulating committed progenitors (PrMC) expressing c-kit
and the membrane-associated aminopeptidase CD13 (17) and
lacking the monocyte-associated lipopolysaccharide receptor
subunit, CD14 (1). In mice, PrMC reside
constitutively in the intestine, permitting the rapid development of an
MC hyperplasia driven by T-cell-derived factors elaborated in response
to infections with helminthic parasites (32). This MC
response is required for the normal elimination of adult helminthic
worms (19). Other experimental evidence supports an
essential role for resident MC in innate immune responses to
gram-negative bacteria (22). Thus, MC participate in both
innate and adaptive protective responses, in addition to their
established role in inflammation and allergy (5).
Information about PrMC homing determinants is limited due to their
small numbers in blood in vivo (17). The culture of human cord blood mononuclear cells (CBMNC) in the presence of the triad of
recombinant soluble SCF, interleukin-6 (IL-6), and IL-10 (the latter for inhibition of monocyte/macrophage growth)
gave rise to cultures primarily composed of human (h)PrMC,
characterized by a c-kit+ CD13+
cytofluorographic profile, by a requirement for SCF to achieve maximal
thymidine incorporation, and by a lack of responses to macrophage
colony-stimulating factor granulocyte (M-CSF), G-CSF, and IL-2
(26). The hPrMC exhibited cytoplasmic staining for chloroacetate esterase (CAE), a marker of the myeloid and MC lineages that does not stain monocytes, macrophages, or basophils. By 9 weeks,
these hPrMC differentiated into mature, fully functional mature hMC
containing strongly CAE-positive secretory granules. hPrMC expressed
four functional chemokine receptors: CXCR2, CCR3, CXCR4, and CCR5. Both
CCR3 and CCR5 can serve as coreceptors for macrophage-tropic (M-tropic)
and dualtropic human immunodeficiency virus (HIV) strains on
CD4+ cells (6), such as macrophages and
dendritic cells; CXCR4 serves as a coreceptor with CD4 for
T-cell-tropic (T-tropic) HIV strains (8). Since hPrMC also
express CD4 (26), these findings led us to investigate
whether HIV strains might enter hPrMC and replicate.
In this study, we demonstrate that hPrMC derived in vitro can be
infected by M-tropic HIV strains via a CCR5-dependent mechanism but not
by CXCR4-utilizing T-tropic strains. Furthermore, infected hPrMC
support M-tropic HIV-1 replication over sustained periods. Because
hPrMC traffic to multiple tissues and abound in tissues where HIV and
simian immunodeficiency virus (SIV) infections are initiated (13,
23, 32), the findings may have implications for the
pathophysiology of the resultant diseases.
Isolation and culture of hPrMC and hMC.
Cord blood
obtained from human placentas after routine cesarean section was
sedimented with dextran, and the mononuclear cell (CBMNC) fraction was
isolated by centrifugation through a cushion of Ficoll-Paque (1.77 g/ml) at 350 × g for 30 min. CBMNC were cultured at
106/ml in RPMI 1640 medium (Gibco BRL, Gaithersburg, Md.)
containing 10% fetal bovine serum, 2 mM L-glutamine, 0.1 mM nonessential amino acids, 100 U of penicillin per ml, 100 mg of
streptomycin per ml, 2 µg of gentamicin per ml (all from Sigma, St.
Louis, Mo.), 0.2 µM 2-mercaptoethanol (Gibco BRL), 100 ng of SCF
(Amgen, Thousand Oaks, Calif.) per ml, 50 ng of IL-6 (R & D Systems,
Minneapolis, Minn.) per ml, and 10 ng of IL-10 (Endogen, Cambridge,
Mass.) per ml, hPrMC were harvested at 4 weeks due to their expression of CAE, c-kit, and CD13, and lack of proliferative responses
to IL-2, G-CSF, and M-CSF at this time point, as previously reported (26). For experiments performed with mature hMC, the
cultures were carried to 9 weeks, by which time more than 98% of the
cells were toluidine blue and tryptase positive.
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.22.10808-10814.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Human Mast Cell Progenitors Can Be Infected by Macrophagetropic
Human Immunodeficiency Virus Type 1 and Retain Virus with
Maturation In Vitro
![]()
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
cells were stained for CAE,
for metachromasia with toluidine blue (26), and Astra
blue (9) prior to studies involving infection to
ensure relative uniformity. In some experiments, the CD14+
cells were similarly assessed after their recovery from the column.
Reagents and antibodies.
Anti-CCR5 antibody (Ab) 2D7
(immunoglobulin G2a [IgG2a]), anti-CXCR4 Ab 12G5 (IgG2a), anti-CD13
(IgG1), anti-CD4 (IgG1 from PharMingen), anti-CD14 (IgG2a), and
recombinant SDF1
were purchased from PharMingen (San Diego, Calif.).
The CCR3-specific Ab 7B11 was obtained from the AIDS Research and
Reagents Program (National Institutes of Health Bethesda, Md.).
Anti-c-kit (K69, IgG1) was purchased from Biosource
International (Camarillo, Calif.). Anti-CD13 (IgG1) and anti-CD14
(IgG2a) were purchased from PharMingen. TAK-779 was provided by Takeda
Chemical Industries (Osaka, Japan). Azidothymidine (AZT) was purchased
from Sigma. The concentrations of the inhibitors used were chosen based
on doses previously shown to reduce HIV entry (2, 4, 12,
31).
Flow cytometry and staining of hPrMC. Flow cytometry was carried out in the presence of cold Hanks' balanced salt solution containing 2% fetal bovine serum, 0.1% human serum, and 0.01% sodium azide (fluorescence-activated cell sorter [FACS] buffer). After fixation for 5 min in FACS buffer containing 3% paraformaldehyde and exposure to monoclonal Abs, the cells were stained with fluorescein isothiocyanate-conjugated sheep anti-mouse IgG (Calbiochem, La Jolla, Calif.) and then analyzed using FACSort (Becton Dickinson, Oxnard, Calif.). The results were analyzed as overlaid histograms. Low-level expression of c-kit and CD13 and lack of CD14 were used to identify hPrMC, as described previously (26), while mature hMC were identified based on a high level of c-kit staining, continued expression of CD13, positive CD14 expression, and a higher relative level of side-angle light scatter (SSC).
HIV-1 replication assay. Replication-competent recombinant NL4-3-ADA and NL4-3-HXBc2 were generated in HeLa cells as described previously (18). hPrMC (4 × 106) were incubated with 105 cpm of reverse transcriptase (RT) activity for 12 h, washed three times with phosphate-buffered saline (PBS), and cultured in 2.5 ml of complete medium with cytokines. Samples (0.5 ml) were removed every third day and replaced by an equal volume of fresh medium with cytokines, and the nonadherent cells were transferred to a new culture vessel. Virus production was determined by measurement of p24gag in the medium with a commercial antigen capture assay kit (NEN Life Science Products, Boston, Mass.).
Env complementation assay.
HIV-1 proviral DNA lacking a
functional env gene and containing the chloramphenicol
acetyltransferase (CAT) gene in place of the nef reading
frame (pHXBH10
envCAT) was cotransfected into HeLa cells together
with plasmids encoding HIV-1 or SIVmac envelope glycoproteins
(6). Supernatants containing recombinant viruses were
added to 4 × 106 cells at a concentration of
105 cpm of RT activity/ml for 12 h at 37°C. The
infected cells were washed three times with PBS and cultured in 3 ml of
regular cytokine-supplemented medium. Five days after infection,
nonadherent cells were lysed and CAT activity was determined
(6).
gag-pol/
env vector pHIvec2.GFP, the
packaging vector pCMV
P1
envpA, psrev, and plasmids encoding HIV-1
envelope glycoproteins, as described previously (14). A
total of 4 × 106 hPrMC were infected with 400,000 RT
units of virus overnight. At 5 to 14 days after infection, infected
cells (0.3 to 2.5% of the total cells 2 weeks after infection;
n = 5 donors) were separated by FACS with the MoFlo
sorter (Cytomation, Fort Collins, Colo.) using the GFP expression as
marker for infection. Sorted cells were stained on slides for CAE
activity and for immunoreactivity for tryptase as described previously
(26).
| |
RESULTS |
|---|
|
|
|---|
Purity of 4-week-old hPrMC and expression of CD4 and HIV
coreceptors.
Cultures of CBMNC that were 4 weeks old were analyzed
for their identity and purity. The crude 4-week-old preparations
contained between 20 and 40% toluidine blue-positive hMC (as shown for
one donor in Fig. 1a).
Cytofluorographic analysis of the crude preparations revealed two
populations differing in SSC as previously reported (as shown for one
donor [Fig. 1b]) (26). The high-SSC population (mature
hMC) was c-kit+, was also CD13+,
expressed CCR3 and some CXCR4 but not CCR5 or CD4 (data not shown), and
was CD14+ (Fig. 1b). The lower SSC population was more
weakly but uniformly c-kit+ and was also
CD13+; more than 95% of this cell population was
CD14
(Fig. 1b). This low-SSC population of hPrMC
expressed CD4, CXCR4, and CCR5, as well as CCR3 (data not shown).
|
cells had toluidine
blue-positive granules (Fig. 1d, left). Virtually all (>98%) were
positive for CAE (n = 3, as shown for one donor [Fig.
1d, center]), and most (~60%) contained Astra blue-positive granules, a marker restricted to MC and basophils (9)
(Fig. 1d, right), suggesting the presence of nascent secretory granules in hPrMC despite their lack of avidity for toluidine blue dye. The
eluted CD14+ fraction contained mostly mature hMC based on
toluidine blue staining, with the remaining cells having morphologic
features consistent with macrophages or monocytes (data not shown).
M-tropic but not T-tropic HIV strains can replicate in hPrMC.
The expression of CD4 and HIV-1 coreceptors suggested that hPrMC might
be susceptible to infection by M-tropic HIV-1 strains (which utilize
CCR5 and, to a lesser extent, CCR3) and T-tropic strains (which utilize
CXCR4). In the background of the NL4-3 strain, the
replication-competent recombinant ADA (M-tropic) virus but not the
HXBc2 (T-tropic) virus replicated in the crude 4-week-old preparations,
as determined by monitoring p24gag levels in the
supernatant (n = 2 [a representative experiment is
shown in Fig. 2]). Progressive increases
in p24gag levels were evident up to day 21 postinfection. The replication was completely inhibited in the presence
of 50 µM AZT. No cytopathic effects were observed with the HIV-1 ADA
strain. Both the ADA and HXBc2 strains replicated in human peripheral
blood mononuclear cells (data not shown).
|
Identity of infected CD14-negative cells as hPrMC and retention
of HIV with maturation.
To demonstrate that the infected
subset of cells was not a minor contaminating population,
purified 4-week-old hPrMC were infected with recombinant
single-round viruses containing the GFP gene and pseudotyped with
HIV-1 YU2 and HXBc2 envelope glycoproteins. The YU2 envelope
glycoproteins, like those of the ADA strain of HIV-1, utilize CCR5 and
CCR3 as coreceptors (6). Five days following incubation of
cells and virus, GFP-positive cells (0.2 to 1% of the total cells)
were present in cultures infected with HIV-1 YU2 pseudotyped viruses
(n = 3, as shown for one experiment [Fig.
3a, right]) but not in cultures infected
with HIV-1 HXBc2 pseudotypes (Fig. 3b). When GFP-positive HIV-1 YU2
infected cells were separated by using FACSort, all of the GFP-positive
cells exhibited diffuse cytoplasmic CAE staining (Fig. 3a, left).
|
Chemokine receptors function as HIV coreceptors on hPrMC.
To
determine the ability of M- and T-tropic HIV-1 viruses and an SIV
strain (SIVmac316) (14) to infect hPrMC and hMC, we performed single-round assays using recombinant CAT-reporter viruses pseudotyped with HIV-1 and SIV envelope glycoproteins. Viruses bearing
CCR5-utilizing envelope glycoproteins (ADA, YU2, and 89.6 strains of
HIV-1 and SIVmac316) entered hPrMC. The highest infectivity level was
detected with viruses carrying the ADA envelope glycoproteins, and the
lowest was detected with the SIVmac316 envelope glycoproteins; the
latter was only slightly above the background measured with the
nonfunctional
KS envelope glycoprotein (16) (Fig.
4a). Pseudotypes containing the envelope
glycoproteins of the primary T-tropic HIV-1 isolate ELI and the
T-cell-line-adapted HIV-1 strain HXBc2 did not infect hPrMC. Thus, the
replication block of HXBc2 in hPrMC is due to restricted or very
inefficient entry, despite considerable CXCR4 and CD4 expression (Fig.
1). Infections performed with purified hPrMC gave consistently higher
levels of CAT activity than did experiments performed with crude hPrMC
cultures. Replicate CD14+ cells recovered after the column
purification (consisting mostly of mature hMC) yielded negligible
levels of CAT activity (n = 2 [data not shown]). The
9-week-old cord blood-derived hMC were not susceptible to new infection
by viruses pseudotyped with ADA, YU2, and HXBc2 envelopes. However,
viruses containing the vesicular stomatitis virus (VSV) G envelope gave
a strong reporter signal in these assays, showing that events in the
HIV-1 life cycle following entry, including reverse transcription and
long terminal repeat-driven transcription, were not restricted
(Fig. 4b).
|
CCR5 is the dominant receptor used by M-tropic strains for entry
into hPrMC.
To determine the coreceptor used by M-tropic HIV-1
strains to infect hPrMC, the virus showing the highest infectivity
(HIV-1 ADA) was used in experiments with specific CCR5, CCR3, and CXCR4 inhibitors to block entry. The CCR5-specific Ab 2D7 and TAK-779, a
nonpeptide compound able to inhibit entry mediated by CCR5 and CCR2b
(4), reduced the infection by more than 80% (Fig.
5). CCR2b is not expressed by hPrMC
(26) and is not used by ADA or most other M-tropic HIV-1
strains. Thus, CCR5 is the major coreceptor for M-tropic HIV-1 isolates
for entry into hPrMC. The CCR3-specific Ab 7B11, but not eotaxin,
slightly decreased entry as well (Fig. 5). The CXCR4-specific Ab 12G5
and recombinant human SDF-1
, the natural ligand for CXCR4, did not
affect entry.
|
| |
DISCUSSION |
|---|
|
|
|---|
This study reveals that hPrMC derived in vitro can be infected by M-tropic and dualtropic, but not T-tropic, HIV strains. The importance of hMC in both innate and adaptive immunity, the ability of hPrMC to home to multiple tissues, their abundance at sites of HIV introduction, and the tendency of tissue hMC to survive for long periods suggest that HIV-infected hPrMC might not only lead to the viral spreading but might also provide a long-lived sanctuary for the virus.
We suspected the potential for HIV infection of hPrMC based on their repertoire of surface coreceptors, CD4, CCR3, CXCR4, and CCR5 (Fig. 1). Crude 4-week-old cultured hPrMC were productively infected with replication-competent viruses containing the envelope genes of an M-tropic HIV-1 isolate (NL4-3-ADA) but not a T-tropic isolate (NL4-3-HXBc2). New virus was produced over a relatively sustained period, peaking at 21 to 24 days (Fig. 2). The infection of hPrMC was confirmed by the fact that FACSort-separated infected GFP-positive cells stained positively for CAE (Fig. 3) after infection with the HIV YU2 construct containing the GFP reporter.
The replication of the M-tropic but not the T-tropic HIV-1 strain led
us to further explore the profiles of viruses able to infect hPrMC
using Env complementation assays. Although hPrMC express abundant
functional CXCR4 as determined by SDF-
-mediated calcium flux
(26), CXCR4-utilizing HIV-1 HXBc2 and ELI strains did not
infect hPrMC in these assays, while all of the M-tropic and dualtropic
HIV-1 strains tested entered hPrMC. Crude and purified hPrMC
populations yielded similar results. Indeed, the levels of HIV-1 ADA
entry were higher in the purified hPrMC than in the crude hPrMC that
contained some CD14+ cells consisting largely of mature
hMC, while the CD14+ cells showed negligible HIV-1 entry
and 9-week-old hMC were not susceptible to infection by any of the HIV
strains tested (Fig. 4B), probably due to their lack of CD4 and CCR5
(26). Nonetheless, postentry events were functional in
hMC, since infection with VSV G-pseudotyped viruses was successful.
Moreover, mature hMC clearly continued to produce HIV as they developed
from infected hPrMC, as indicated by the staining characteristics of
the FACSort-separated cells 2 weeks after infection with the HIV YU2
construct containing the GFP reporter (Fig. 3c and d). These
observations are consistent with the recent report of HIV-bearing,
metachromatic, tryptase- and chymase-positive hMC-like cells in the
blood of patients with AIDS (21).
There are several possible explanations for the lack of CXCR4 utilization by HIV1 in hPrMC. A replication block is reported for several other cells including macrophages, microglia, G0 stem cells, and a subset of a hematopoietic cell line (2, 25, 30), which all express CXCR4 along with CD4 but are resistant to productive infection. The pattern of posttranslational modifications of the CXCR4 extracellular domains or the ability to form a signaling-competent transient gp120-CD4-CXCR4 complex (3, 7, 20) may also dictate the strain specificity of HIV-1 entry into hPrMC. Additional postentry restrictions, although not evident in our study, were reported previously for human macrophages (31).
Coreceptor utilization on hPrMC by M-tropic HIV-1 strains was
determined with specific CCR5, CCR3, and CXCR4 inhibitors to block
entry of the ADA pseudotype in single-round infections. Both the
CCR5-specific Ab 2D7 and the nonpeptide compound TAK-779 (4) reduced the infection of hPrMC by more than 80% (Fig.
5), strongly indicating that CCR5 is the major coreceptor used by M-tropic HIV-1 isolates to enter hPrMC. While the CCR3 ligand eotaxin
did not inhibit virus infection in this assay, the CCR3-specific Ab
7B11 slightly (~20%) inhibited entry. Thus, CCR3 might also function
as a coreceptor on these cells. Similar results were obtained with
human microglia (2, 12). Neither the CXCR4-specific Ab
12G5 nor recombinant human SDF-1
affected entry. Thus, as with
dendritic cells (11, 28), hPrMC could serve to initiate the spread of HIV after becoming infected with the M-tropic strains that are consistently isolated during the initial stages of disease.
Our findings show that hPrMC can be productively infected by M-tropic HIV-1 strains in vitro. These observations carry potential implications for the pathophysiology of HIV. hPrMC in the intestinal mucosa could support initial infection with M-tropic HIV strains that are critical to the initiation of HIV disease. The migration of infected hPrMC or hMC to secondary lymphoid organs could facilitate the transfer of HIV to CD4-positive lymphocytes; indeed, hMC infiltrate local lymph nodes in certain inflammatory circumstances (34) and cervical lymph nodes from patients with AIDS contain increased numbers of hMC compared with normal controls (27). Additionally, hMC is one of the few immune cell types found in the normal central nervous system and brain (33). If hPrMC become infected during the viremic phase of HIV, they could potentially carry M-tropic HIV across the blood-brain barrier for transfer to microglia and astrocytes, which, like hPrMC, are susceptible to infection via CCR5 and CCR3 (12). Since hMC are long-lived in vivo and shed active virus for sustained periods (Fig. 2), infected hMC could provide a sustained source of viral production at mucosal and cutaneous sites. Indeed, the numbers of hMC observed in the submucosa and lamina propria of the intestines of HIV-infected patients are normal, even though the numbers of hMC in the adjacent epithelium are diminished, probably reflecting the requirement of this anatomic subset of hMC for normal T-cell function (15). Finally, it is possible that HIV infection could alter the function of hMC or their threshold for activation, since both urticaria (10) and intractable pruritus (24) are associated with HIV infection.
| |
ACKNOWLEDGMENTS |
|---|
N. Bannert and J. A. Boyce contributed equally to this work.
This work was supported by National Institutes of Health grants AI-01305, AI-31599, AI-22531, and HL-36110 and by a grant from the Hyde and Watson Foundation. N.B. was supported by a fellowship from the Deutsche Forschungsgemeinschaft (DFG).
We acknowledge Nancy Kedersha for providing her expertise in the use of fluorescence microscopy.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Division of Rheumatology, Immunology and Allergy, Brigham and Woman's Hospital, Smith Bldg. Rm. 618, 1 Jimmy Fund Way, Boston, MA 02115. Phone: (617) 525-1233. Fax: (617) 525-1310. E-mail: Jboyce{at}rics.bwh.harvard.edu.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Agis, H.,
M. Willheim,
W. R. Sperr,
A. Wilfing,
E. Kromer,
E. Kabrna,
E. Spanblochl,
H. Strobl,
K. Geissler,
A. Spittler,
G. Boltz-Nitulescu,
O. Majdic,
K. Lechner, and P. Valent.
1993.
Monocytes do not make mast cells when cultured in the presence of SCF. Characterization of the circulating mast cell progenitor as a c-kit+, CD34+, Ly , CD14 , CD17 , colony-forming cell.
J. Immunol.
151:4221-4227[Abstract].
|
| 2. |
Albright, A. V.,
J. T. Shieh,
T. Itoh,
B. Lee,
D. Pleasure,
M. J. O'Connor,
R. W. Doms, and F. Gonzales-Scarano.
1999.
Microglia express CCR5, CXCR4, and CCR3, but of these, CCR5 is the principal coreceptor for human immunodeficiency virus type 1 dementia isolates.
J. Virol.
73:205-213 |
| 3. |
Arthos, J.,
A. Rubbert,
R. L. Rabin,
C. Cicala,
E. Machado,
K. Wild,
M. Hanbach,
T. D. Steenbeke,
R. Swofford,
J. M. Farber, and A. S. Fauci.
2000.
CCR5 signal transduction in macrophages by human immunodeficiency virus and simian immunodeficiency virus envelopes.
J. Virol.
74:6418-6424 |
| 4. |
Baba, M.,
O. Nishimura,
N. Kanzaki,
M. Okamoto,
H. Sawada,
Y. Iizawa,
M. Shiraishi,
Y. Aramaki,
K. Okonogi,
Y. Ogawa,
K. Meguro, and M. Fujino.
1999.
A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity.
Proc. Natl. Acad. Sci. USA
96:5698-5703 |
| 5. | Casale, T. B., D. Wood, H. B. Richerson, B. Zehr, D. Zavala, and G. W. Hunninghake. 1987. Direct evidence of a role for mast cells in the pathogenesis of antigen-induced bronchoconstriction. J. Clin. Investig. 80:1507-1511. |
| 6. |
Choe, H.,
M. Farzan,
Y. Sun,
N. Sullivan,
B. Rollins,
P. D. Ponath,
L. Wu,
C. R. Mackay,
G. LaRosa,
W. Newman,
N. Gerard,
C. Gerard, and J. Sodroski.
1996.
The -chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates.
Cell
85:1135-1148[CrossRef][Medline].
|
| 7. | Dimitrov, D. S., D. Norwood, T. S. Stantchev, Y. Feng, X. Xiao, and C. C. Broder. 1999. A mechanism of resistance to HIV-1 entry: inefficient interactions of CXCR4 with CD4 and gp120 in macrophages. Virology 259:1-6[CrossRef][Medline]. |
| 8. |
Doranz, B.,
J. J. Rucker,
Y. Yi,
R. J. Smyth,
M. Samson,
S. C. Peiper,
M. Parmentier,
R. G. Collman, and R. W. Doms.
1996.
A dual-tropic primary HIV-1 isolate that uses fusin and the -chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors.
Cell
85:1149-1158[CrossRef][Medline].
|
| 9. | Duffy, J. P., P. J. Smith, J. Crocker, and H. R. Matthews. 1993. Combined staining method for the demonstration of tissue eosinophils and mast cells. J. Histochem. Cytochem. 16:143-144. |
| 10. | Duvic, M. 1995. Human immunodeficiency virus and the skin: selected controversies. J. Investig. Dermatol. 105:117S-121S[CrossRef][Medline]. |
| 11. |
Granelli-Piperno, A.,
B. Moser,
M. Pope,
D. Chen,
Y. Wei,
F. Isdell,
U. O'Doherty,
W. Paxton,
R. Koup,
S. Mojsov,
N. Bhardwaj,
I. Clark-Lewis,
M. Baggiolini, and R. M. Steinman.
1996.
Efficient interaction of HIV-1 with purified dendritic cells via multiple chemokine coreceptors.
J. Exp. Med.
184:2433-2438 |
| 12. | He, J., Y. Chen, M. Farzan, H. Choe, A. Ohagen, S. Gartner, J. Busciglio, X. Yang, W. Hofmann, W. Newman, C. R. Mackay, J. Sodroski, and D. Gabuzda. 1997. CCR3 and CCR5 are coreceptors for HIV-1 infection of microglia. Nature 385:645-649[CrossRef][Medline]. |
| 13. | Heise, C., P. Vogel, C. J. Lackner, and S. Dandekar. 1993. Distribution of SIV infection in the gastrointestinal tract of rhesus macaques at early and terminal stages of AIDS. J. Med. Primatol. 22:187-193[Medline]. |
| 14. |
Hofmann, W.,
D. Schubert,
J. LaBonte,
L. Munson,
S. Gibson,
J. Scammell,
P. Ferrigno, and J. Sodroski.
1999.
Species-specific, postentry barriers to primate immunodeficiency virus infection.
J. Virol.
73:10020-10028 |
| 15. | Irani, A. A., S. S. Craig, G. DeBlois, C. O. Elson, N. M. Schechter, and L. B. Schwartz. 1987. Deficiency of the tryptase-positive, chymase-negative mast cell type in gastrointestinal mucosa of patients with defective T lymphocyte function. J. Immunol. 138:4381-4386[Abstract]. |
| 16. |
Karlsson, G. B.,
M. Halloran,
D. Schenten,
J. Lee,
P. Racz,
K. Tenner-Racz,
J. Manola,
R. Gelman,
B. Etemad-Moghadam,
E. Desjardins,
R. Wyatt,
N. P. Gerard,
L. Marcon,
D. Margolin,
J. Fanton,
M. K. Axthelm,
N. L. Letvin, and J. Sodroski.
1998.
The envelope glycoprotein ectodomains determine the efficiency of CD4+ T lymphocyte depletion in simian-human immunodeficiency virus-infected macaques.
J. Exp. Med.
188:1159-1171 |
| 17. |
Kirshenbaum, A. S.,
J. P. Goff,
T. Semere,
B. Foster,
L. M. Scott, and D. D. Metcalfe.
1999.
Demonstration that mast cells arise from a progenitor cell population that is CD34+, c-kit+, and expresses aminopeptidase N (CD13).
Blood
94:2333-2342 |
| 18. |
Kolchinsky, P.,
T. Mirzabekov,
M. Farzan,
E. Kiprilov,
M. Cayabyab,
L. J. Mooney,
H. Choe, and J. Sodroski.
1999.
Adaptation of a CCR5-using, primary human immunodeficiency virus type 1 isolate for CD4-independent replication.
J. Virol.
73:8120-8126 |
| 19. | Lantz, C. S., J. Boesiger, C. H. Song, N. Mach, T. Kobayashi, R. C. Mulligan, Y. Nawa, G. Dranoff, and S. J. Galli. 1998. Role for interleukin-3 in mast cell and basophil development and in immunity to parasites. Nature 392:90-93[CrossRef][Medline]. |
| 20. | Lapham, C. K., M. B. Zaitseva, S. Lee, T. Romanstseva, and H. Golding. 1999. Fusion of monocytes and macrophages with HIV-1 correlates with biochemical properties of CXCR4 and CCR5. Nat. Med. 5:303-308[CrossRef][Medline]. |
| 21. |
Li, Y.,
L. Li,
R. Wadley,
S. W. Reddel,
J. C. Qi,
C. Archis,
A. Collins,
E. Clark,
M. Cooley,
S. Kouts,
H. M. Naif,
M. Alali,
A. Cunningham,
G. W. Wong,
R. L. Stevens, and S. A. Krilis.
2001.
Mast cells/basophils in the peripheral blood of allergic individuals who are HIV-1 susceptible due to their surface expression of CD4 and the chemokine receptors CCR3, CCR5, and CXCR4.
Blood
97:3484-3490 |
| 22. | Malaviya, R., T. Ikeda, E. Ross, and S. N. Abraham. 1996. Mast cell modulation of neutrophil influx and bacterial clearance at sites of infection through TNF-alpha. Nature 381:77-80[CrossRef][Medline]. |
| 23. | McNeil, H. ., and K. F. Austen. 1995. Biology of the mast cell, p. 185-201. In M. M. Frank, K. F. Austen, H. N. Claman, and E. R. Unanue (ed.), Samter's immunologic diseases, 5th ed. Little, Brown, Boston, Mass. |
| 24. | Milazzo, F., S. Piconi, D. Trabattoni, C. Magni, M. Coen, A. Capetti, M. L. Fusi, C. Parravicini, and M. Clerici. 1999. Intractable pruritus in HIV infection: immunologic characterization. Allergy 54:266-272[CrossRef][Medline]. |
| 25. |
Moriuchi, H.,
M. Moriuchi, and A. S. Fauci.
1998.
Differentiation of promonocytic U937 subclones into macrophage-like phenotypes regulates a cellular factor(s) which modulates fusion/entry of macrophage tropic human immunodeficiency virus type 1.
J. Virol.
72:3394-3400 |
| 26. |
Ochi, H.,
W. M. Hirani,
Q. Yuan,
D. Friend,
K. F. Austen, and J. A. Boyce.
1999.
T helper cell type 2 cytokine-mediated comitogenic responses and CCR3 expression during differentiation of human mast cells in vitro.
J. Exp. Med.
190:267-280 |
| 27. | Paiva, D. D., J. C. Morais, J. Pilotto, V. Veloso, F. Duarte, and H. L. Lenzi. 1996. Spectrum of morphologic changes of lymph nodes in HIV infection. Mem. Inst. Oswaldo Cruz 91:371-379[Medline]. |
| 28. |
Reece, J. C.,
A. J. Handley,
E. J. Anstee,
W. A. Morrison,
S. M. Crowe, and P. U. Cameron.
1998.
HIV-1 selection by epidermal dendritic cells during transmission across human skin.
J. Exp. Med.
187:1623-1631 |
| 29. | Saito, H., M. Ebisawa, H. Tachimoto, M. Shichijo, K. Fukagawa, K. Matsumoto, Y. Iikura, T. Awaji, G. Tsujimoto, M. Yanagida, H. Uzumaki, G. Takahashi, K. Tsuji, and T. Nakahata. 1996. Selective growth of human mast cells induced by steel factor, interleukin 6, and prostaglandin E2 from cord blood mononuclear cells. J. Immunol. 157:343-350[Abstract]. |
| 30. |
Schen, H.,
T. Cheng,
F. I. Preffer,
D. Dombkowski,
M. H. Tomasson,
D. E. Golan,
O. Yang,
W. Hofmann,
J. G. Sodroski,
A. D. Luster, and D. T. Scadden.
1999.
Intrinsic human immunodeficiency virus type 1 resistance of hematopoietic stem cells despite coreceptor expression.
J. Virol.
73:728-737 |
| 31. |
Schmidtmayerova, H.,
M. Alfano,
G. Nuovo, and M. Bukrinsky.
1998.
Human immunodeficiency virus type 1 T-lymphotropic strains enter macrophages via a CD4- and CXCR4-mediated pathway: replication is restricted at a postentry level.
J. Virol.
72:4633-4642 |
| 32. | Schrader, J. W., R. Scollay, and F. Battye. 1983. Intramucosal lymphocytes of the gut: Lyt-2 and Thy-1 phenotype of the granulated cells and evidence for the presence of both T cells and mast cell precursors. J. Immunol. 130:558-564[Abstract]. |
| 33. | Silver, R., A. J. Silverman, L. Vitkovic, and I. I. Lederhendler. 1996. Mast cells in the brain: evidence and functional significance. Trends Neurosci. 19:25-31[CrossRef][Medline]. |
| 34. | Wang, H.-W., N. Tedia, A. R. Lloyd, D. Wakefield, and H. P. McNeil. 1998. Mast cell activation and migration to lymph nodes during induction of an immune response in mice. J. Clin. Investig. 102:1617-1626[Medline]. |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»